These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27479154)

  • 21. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.
    Guo H; Albrecht S; Bourdeau M; Petzke T; Bergeron C; LeBlanc AC
    Am J Pathol; 2004 Aug; 165(2):523-31. PubMed ID: 15277226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for FKBP52 in Tau protein function.
    Chambraud B; Sardin E; Giustiniani J; Dounane O; Schumacher M; Goedert M; Baulieu EE
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2658-63. PubMed ID: 20133804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies.
    Ferreira A; Bigio EH
    Mol Med; 2011; 17(7-8):676-85. PubMed ID: 21442128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease.
    Rohn TT; Head E; Su JH; Anderson AJ; Bahr BA; Cotman CW; Cribbs DH
    Am J Pathol; 2001 Jan; 158(1):189-98. PubMed ID: 11141492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions.
    Togo T; Akiyama H; Iseki E; Uchikado H; Kondo H; Ikeda K; Tsuchiya K; de Silva R; Lees A; Kosaka K
    Acta Neuropathol; 2004 Jun; 107(6):504-8. PubMed ID: 15024583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuropathology of tauopathy].
    Yoshida M
    Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tau function and dysfunction in neurons: its role in neurodegenerative disorders.
    Avila J; Lim F; Moreno F; Belmonte C; Cuello AC
    Mol Neurobiol; 2002 Jun; 25(3):213-31. PubMed ID: 12109872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of WO2011045166A1, Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction.
    Zheng F; Zhang B; Sun Y; Qiu M; Su J
    Expert Opin Ther Pat; 2015 Jul; 25(7):831-5. PubMed ID: 25945965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease.
    Guillozet-Bongaarts AL; Garcia-Sierra F; Reynolds MR; Horowitz PM; Fu Y; Wang T; Cahill ME; Bigio EH; Berry RW; Binder LI
    Neurobiol Aging; 2005 Jul; 26(7):1015-22. PubMed ID: 15748781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.
    Huang Y; Liu XQ; Wyss-Coray T; Brecht WJ; Sanan DA; Mahley RW
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8838-43. PubMed ID: 11447277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteins recruited to exosomes by tau overexpression implicate novel cellular mechanisms linking tau secretion with Alzheimer's disease.
    Saman S; Lee NC; Inoyo I; Jin J; Li Z; Doyle T; McKee AC; Hall GF
    J Alzheimers Dis; 2014; 40 Suppl 1(Suppl 1):S47-70. PubMed ID: 24718102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo.
    Guillozet-Bongaarts AL; Cahill ME; Cryns VL; Reynolds MR; Berry RW; Binder LI
    J Neurochem; 2006 May; 97(4):1005-14. PubMed ID: 16606369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease.
    Girardot N; Allinquant B; Langui D; Laquerrière A; Dubois B; Hauw JJ; Duyckaerts C
    Neuropathol Appl Neurobiol; 2003 Oct; 29(5):451-61. PubMed ID: 14507337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies.
    Bakota L; Ussif A; Jeserich G; Brandt R
    Mol Cell Neurosci; 2017 Oct; 84():132-141. PubMed ID: 28318914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxic tau aggregation in AD.
    Takashima A
    Adv Exp Med Biol; 2015; 822():3-9. PubMed ID: 25416970
    [No Abstract]   [Full Text] [Related]  

  • 38. The Neurotoxic Role of Extracellular Tau Protein.
    Sebastián-Serrano Á; de Diego-García L; Díaz-Hernández M
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitration of tau protein is linked to neurodegeneration in tauopathies.
    Horiguchi T; Uryu K; Giasson BI; Ischiropoulos H; LightFoot R; Bellmann C; Richter-Landsberg C; Lee VM; Trojanowski JQ
    Am J Pathol; 2003 Sep; 163(3):1021-31. PubMed ID: 12937143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.
    Wennström M; Janelidze S; Nilsson KPR; ; Serrano GE; Beach TG; Dage JL; Hansson O
    Acta Neuropathol Commun; 2022 Jan; 10(1):3. PubMed ID: 34991721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.